Hemerion completed the database lock for its HTX-GBM-01 clinical study on September 28, 2026. This key clinical development milestone formally closes data collection and marks the start of the final statistical analysis.
The clinical database lock for the HTX-GBM-01 trial represents another major clinical development milestone for the Heliance® interventional oncology platform in the treatment of glioblastoma, the most common and aggressive malignant primary brain tumor.
Study Objectives: Feasibility, Safety, and Tolerability
HTX-GBM-01 is a Phase 1/2 trial primarily aimed at evaluating the feasibility and safety of photodynamic therapy enabled by the Heliance® platform. The study protocol also incorporates testing of two light doses (200 and 400 J/cm²) to further define treatment tolerability.
In addition to safety endpoints evaluated over a six-month follow-up period, the dataset includes secondary efficacy endpoints, notably progression-free survival at six months (PFS-6).
Seamless Integration into Surgical Workflow and Standard of Care
The study also collected human factors and platform ergonomics data through feedback from surgeons and operating room staff following each procedure.
Conducted across sites in Europe and the United States, it was designed to assess how the platform fits into standard surgical workflows within diverse international surgical and regulatory environments.
Key Preliminary Results
The initial findings of this study have been presented at the 2026 Society of Neuro Oncology Annual Meeting by Pr. Constantinos G. Hadjipanayis (Executive Vice Chair of Neurological Surgery & Co-Director, UPMC Brain Tumor Center) :
- Seamless OR Workflow: The full prescribed light dose was delivered in 100% of patients, with median treatment times of just 16.1 minutes (200 J/cm²) and 26.1 minutes (400 J/cm²) – all completed in under 30 minutes.
Preparing the pivotal phase 3 study in the U.S. and Europe
Hemerion expects to finalize the clinical study report by the end of 2026 in preparation for regulatory submissions to the relevant health authorities, including the FDA in the United States and European regulatory bodies such as the ANSM in France.
Full efficacy and safety results from the HTX-GBM-01 study will subsequently be published in a peer-reviewed scientific journal, authored by the clinical investigators: Dr. Constantinos Hadjipanayis and Dr. Jan Drappatz of the University of Pittsburgh, and Prof. Nicolas Reyns of Lille University Hospital (CHU de Lille).